Enliven Therapeutics (ELVN) Total Non-Current Liabilities (2022 - 2025)

Enliven Therapeutics (ELVN) has 4 years of Total Non-Current Liabilities data on file, last reported at $14.6 million in Q3 2025.

• For the quarter ending Q3 2025, Total Non-Current Liabilities fell 13.96% year-over-year to $14.6 million; the trailing twelve-month figure through Sep 2025 stood at $14.6 million (down 13.96% YoY), and the FY2024 full-year result was $15.9 million, down 38.54% from the prior year.
• Total Non-Current Liabilities declined to $14.6 million in Q3 2025, from $15.2 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $25.9 million in Q4 2023 to a low of $9.1 million in Q2 2023.
• A 4-year average of $16.0 million and a median of $14.9 million in 2025 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities surged 166.54% in 2023 and plunged 44.18% in 2025, its largest moves.
• Tracing ELVN's Total Non-Current Liabilities over 4 years: stood at $9.7 million in 2022, then surged by 166.54% to $25.9 million in 2023, then plunged by 38.54% to $15.9 million in 2024, then slipped by 7.95% to $14.6 million in 2025.
• Business Quant data shows ELVN's Total Non-Current Liabilities at $14.6 million in Q3 2025, $15.2 million in Q2 2025, and $14.0 million in Q1 2025.